Briacell Therap (NASDAQ:BCTX) Issues Quarterly Earnings Results

Posted by Amy Steele on Mar 11th, 2026

Briacell Therap (NASDAQ:BCTX – Get Free Report) issued its earnings results on Tuesday. The company reported ($2.58) EPS for the quarter, Zacks reports.

Briacell Therap Trading Up 7.5%

Shares of BCTX traded up $0.29 during midday trading on Wednesday, hitting $4.10. 107,043 shares of the company’s stock traded hands, compared to its average volume of 569,668. The stock has a market capitalization of $29.69 million, a price-to-earnings ratio of -0.09 and a beta of 1.46. Briacell Therap has a 1 year low of $3.60 and a 1 year high of $98.20. The firm’s fifty day moving average is $4.87 and its 200-day moving average is $8.20.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Briacell Therap stock. Citadel Advisors LLC purchased a new stake in Briacell Therap (NASDAQ:BCTX – Free Report) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 11,055 shares of the company’s stock, valued at approximately $122,000. Citadel Advisors LLC owned about 1.63% of Briacell Therap as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 15.42% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Briacell Therap in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $320.00.

Check Out Our Latest Analysis on BCTX

About Briacell Therap

(Get Free Report)

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.